The mechanism remains unclear, but GLP-1 users had less MACE, CV death, and all-cause death driven by fewer amputations.

Overcoming clinical inertia around starting and intensifying antihypertensive drugs is key, a researcher says.

The agency says there have been 22 injuries and no deaths associated with this potentially high-risk device issue.

Transparency is needed to improve equity, though it can be awkward to talk about salary, says Thomas MacGillivray.

Topics spanned from GLP-1s to aorto-coronary bypass without surgery, Lp(a)’s extended reach, US dietary guidelines, and more.

Observational data point to the scope of opportunity that lies in GLP-1 drugs, SGLT2 inhibitors, and nonsteroidal MRAs.

The study supports “more is more” when it comes to arterial conduits until additional RCT data arrive, researcher says.

This “long overdue” update expands the pools of patients eligible for thrombolysis and thrombectomy, and tackles pediatric ...

The system enters a field that sees PFA catheters largely displacing thermal modalities for catheter ablation of AF.

NEW ORLEANS, LA—A risk model based on data from the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database (ACSD) ...

Cases exceeding the 90th percentile for dose, though infrequent, resulted in greater cumulative exposures for all cath lab ...

REUP avoids the ethical issues and costs of other procurement and recovery methods. So far, outcomes are excellent.